GLP1_NEW
Semaglutide and bimagrumab 1.0 to 30 mg injection once weekly
BIMASEMA_SC_1p0-30MG_QW
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 40 to 104 (target week 68) | Placebo | MD 1.58 (-10.11 to 12.83) | 0.32 |
| Overweight or obesity without diabetes (adults) | Weight loss of 5 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 32.35 (5.38 to 276) | 0.72 |
| Overweight or obesity without diabetes (adults) | Weight loss of 10 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 16.73 (4.66 to 55.03) | 0.75 |
| Overweight or obesity without diabetes (adults) | Weight loss of 15 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 17.23 (5.84 to 48.24) | 0.81 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.85 (0.25 to 2.74) | 0.60 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 2.73 (0.85 to 8.26) | 0.40 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 2.43 (1.27 to 4.63) | 0.69 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 2.58 (0.90 to 7.30) | 0.67 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 3.47 (1.70 to 7.18) | 0.24 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 2.91 (1.14 to 7.23) | 0.35 |